Knowing a drug’s bioavailability during lead optimization is crucial as it directly influences dosing strategy, therapeutic efficacy, safety margins, and formulation design. Historically, bioavailability estimates have relied heavily on animal studies, which are not only expensive but often fail to predict human in vivo outcomes accurately. Additionally, traditional approaches rely on isolated in vitro assays that also … Continue reading Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies